세계의 자궁경부암 백신 시장 리포트(2023년)

“Cervical Cancer Vaccine Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cervical cancer vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cervical cancer vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The cervical cancer vaccine market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Cervarix; Gardasil; Gardasil 9
• 2) By Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By End-Users: Hospital; Biotechnology Company; Academic And Research Organizations; Other End-Users
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co Inc.; Novartis AG; Sanofi Pasteur
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the cervical cancer vaccine market are: Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Novartis AG, Sanofi Pasteur, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Serum Institute of India (SII), Walvax Biotechnology Co Limited, Bavarian Nordic A/S, CureVac N.V, Profectus Biosciences Inc., Genexine Inc., Inovio Pharmaceuticals Inc., Aston Scientific Inc., Ultimovacs ASA, Nykode Therapeutics AS, Heat Biologics Inc., Northwest Biotherapeutics Inc., VBI Vaccines Inc., OncBioMune Pharmaceuticals Inc., Advaxis Inc., and Immunovaccine Inc.

The global cervical cancer vaccine market is expected to grow from $3.55 billion in 2022 to $4.01 billion in 2023 at a compound annual growth rate (CAGR) of 12.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cervical cancer vaccine market is expected to reach $6.23 billion in 2027 at a CAGR of 11.6%.

The cervical cancer vaccine market consists of sales of a gardiquimod, V503, silgard, and Human papillomavirus vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The cervical cancer vaccine refers to a vaccine that is specifically developed to prevent the occurrence of cervical cancer by targeting the high-risk types of human papillomavirus (HPV) that are responsible for most cases of cervical cancer. The vaccines stimulate an immune response in the body, producing antibodies that can recognize and neutralize the HPV virus.

North America was the largest region in the cervical cancer vaccine market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cervical cancer vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of cervical cancer vaccines are cervarix, gardasil, and gardasil 9. Cervarix is a cervical cancer vaccine that is used to protect against certain strains of the human papillomavirus (HPV) known to cause cervical cancer. The vaccines are sold through distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies to various end-users, including hospitals, biotechnology companies, academic and research organizations, and others.

The rising prevalence of cervical cancer cases is expected to propel the growth of the cervical cancer vaccine market going forward. Cervical cancer refers to a type of cancer that affects the lower part of the uterus (womb), the cervix, which connects to the upper part of the vagina. The rising number of cervical cancer cases is mostly driven by a lack of Human papillomavirus vaccines (HPV) vaccination, a lack of hygiene, and insufficient awareness and knowledge about cervical cancer. Cervical cancer vaccines are highly effective in preventing the development of cervical cancer by targeting the high-risk types of human papillomavirus (HPV). For instance, according to the World Health Organization (WHO), a United Nations agency responsible for international public health, cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases in 2020 and causing around 342,000 deaths. Therefore, the rising number of cervical cancer cases is driving the growth of the cervical cancer vaccine market.

Product innovation has emerged as a key trend gaining popularity in the cervical cancer vaccine market. Leading market players are focusing their resources on developing groundbreaking products to fortify their market presence. For instance, in May 2022, GlaxoSmithKline, a UK-based pharmaceutical company, received approval from the National Medical Products Administration (NMPA) for its two-dose vaccine schedule, Cervarix, for girls ages nine to fourteen to prevent cervical cancer. With the granted approval, Cervarix has become the first two-dose imported HPV vaccine for this age group in mainland China.

In November 2021, the United Nations Population Fund (UNFPA), a United Nations agency, and Roche Diagnostics entered into a partnership agreement with the aim of advancing efforts to eliminate cervical cancer in Eastern Europe and Central Asia. The partnership between UNFPA and Roche Diagnostics underscores their shared commitment to addressing the high burden of cervical cancer in the region and improving access to essential screening services. The goal is to ensure that women in Eastern Europe and Central Asia have increased access to HPV testing and early detection, leading to timely treatment and improved outcomes. Roche Diagnostics is a Switzerland-based company that is involved in the discovery, development, and manufacturing of in vitro tests for various diseases.

The countries covered in the cervical cancer vaccine market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The cervical cancer vaccine market research report is one of a series of new reports from The Business Research Company that provides cervical cancer vaccine market statistics, including the cervical cancer vaccine industry global market size, regional shares, competitors with a cervical cancer vaccine market share, detailed cervical cancer vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the cervical cancer vaccine industry. This cervical cancer vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Table of Contents

1. Executive Summary

2. Cervical Cancer Vaccine Market Characteristics

3. Cervical Cancer Vaccine Market Trends And Strategies

4. Cervical Cancer Vaccine Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On Online Therapy Services Market
• 4.2. Ukraine-Russia War Impact On Online Therapy Services Market
• 4.3. COVID-19 Impact On Online Therapy Services Market
• 5.1. Global Cervical Cancer Vaccine Historic Market Size and Growth, 2017 - 2022, Value ($ Billion)
• 5.2. Global Cervical Cancer Vaccine Forecast Market Size and Growth, 2022 - 2027, 2032F, Value ($ Billion)
• 5.3. Global Cervical Cancer Vaccine Market Drivers and Restraints
  • 5.3.1. Drivers Of The Market
  • 5.3.2. Restraints Of The Market

6. Cervical Cancer Vaccine Market Segmentation

• 6.1. Global Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Cervarix
• Gardasil
• Gardasil 9
• 6.2. Global Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospital
• Biotechnology Company
• Academic And Research Organizations
• Other End-Users

7. Cervical Cancer Vaccine Market Regional And Country Analysis

• 7.1. Global Cervical Cancer Vaccine Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Cervical Cancer Vaccine Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Cervical Cancer Vaccine Market

• 8.1. Asia-Pacific Cervical Cancer Vaccine Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.4. Asia-Pacific Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Cervical Cancer Vaccine Market

• 9.1. China Cervical Cancer Vaccine Market Overview
• 9.2. China Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.4. China Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Cervical Cancer Vaccine Market

• 10.1. India Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.3. India Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Cervical Cancer Vaccine Market

• 11.1. Japan Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.3. Japan Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Cervical Cancer Vaccine Market

• 12.1. Australia Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.3. Australia Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Cervical Cancer Vaccine Market

• 13.1. Indonesia Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.3. Indonesia Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Cervical Cancer Vaccine Market

• 14.1. South Korea Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.3. South Korea Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Cervical Cancer Vaccine Market

• 15.1. Western Europe Cervical Cancer Vaccine Market Overview
• 15.2. Western Europe Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.4. Western Europe Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Cervical Cancer Vaccine Market

• 16.1. UK Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.3. UK Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Cervical Cancer Vaccine Market

• 17.1. Germany Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.3. Germany Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Cervical Cancer Vaccine Market

• 18.1. France Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.3. France Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Italy Cervical Cancer Vaccine Market

• 19.1. Italy Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.2. Italy Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Italy Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Spain Cervical Cancer Vaccine Market

• 20.1. Spain Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Spain Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.3. Spain Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. Eastern Europe Cervical Cancer Vaccine Market

• 21.1. Eastern Europe Cervical Cancer Vaccine Market Overview
• 21.2. Eastern Europe Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. Eastern Europe Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.4. Eastern Europe Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. Russia Cervical Cancer Vaccine Market

• 22.1. Russia Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.2. Russia Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. Russia Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. North America Cervical Cancer Vaccine Market

• 23.1. North America Cervical Cancer Vaccine Market Overview
• 23.2. North America Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. North America Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.4. North America Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. USA Cervical Cancer Vaccine Market

• 24.1. USA Cervical Cancer Vaccine Market Overview
• 24.2. USA Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.3. USA Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.4. USA Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Canada Cervical Cancer Vaccine Market

• 25.1. Canada Cervical Cancer Vaccine Market Overview
• 25.2. Canada Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Canada Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.4. Canada Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. South America Cervical Cancer Vaccine Market

• 26.1. South America Cervical Cancer Vaccine Market Overview
• 26.2. South America Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. South America Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.4. South America Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Brazil Cervical Cancer Vaccine Market

• 27.1. Brazil Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 27.2. Brazil Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 27.3. Brazil Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

28. Middle East Cervical Cancer Vaccine Market

• 28.1. Middle East Cervical Cancer Vaccine Market Overview
• 28.2. Middle East Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 28.3. Middle East Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 28.4. Middle East Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

29. Africa Cervical Cancer Vaccine Market

• 29.1. Africa Cervical Cancer Vaccine Market Overview
• 29.2. Africa Cervical Cancer Vaccine Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 29.3. Africa Cervical Cancer Vaccine Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 29.4. Africa Cervical Cancer Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

30. Cervical Cancer Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Cervical Cancer Vaccine Market Competitive Landscape
• 30.2. Cervical Cancer Vaccine Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Sanofi Pasteur
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Cervical Cancer Vaccine Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. GlaxoSmithKline plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Moderna Inc.
• 31.6. BioNTech SE
• 31.7. CSL Limited
• 31.8. Daiichi Sankyo Company Limited
• 31.9. Sinovac Biotech Ltd.
• 31.10. Bharat Biotech International Limited
• 31.11. Serum Institute of India (SII)
• 31.12. Walvax Biotechnology Co Limited
• 31.13. Bavarian Nordic A/S
• 31.14. CureVac N.V
• 31.15. Profectus Biosciences Inc.

32. Global Cervical Cancer Vaccine Market Competitive Benchmarking

33. Global Cervical Cancer Vaccine Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Cervical Cancer Vaccine Market

35. Cervical Cancer Vaccine Market Future Outlook and Potential Analysis

• 35.1 Cervical Cancer Vaccine Market In 2027 - Countries Offering Most New Opportunities
• 35.2 Cervical Cancer Vaccine Market In 2027 - Segments Offering Most New Opportunities
• 35.3 Cervical Cancer Vaccine Market In 2027 - Growth Strategies
• 35.3.1 Market Trend Based Strategies
• 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer